These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29706106)

  • 1. The Impact of Pazopanib on the Cardiovascular System.
    Justice CN; Derbala MH; Baich TM; Kempton AN; Guo AS; Ho TH; Smith SA
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):387-398. PubMed ID: 29706106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concise drug review: pazopanib and axitinib.
    van Geel RM; Beijnen JH; Schellens JH
    Oncologist; 2012; 17(8):1081-9. PubMed ID: 22733795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
    Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
    Erdogan B; Kostek O; Bekir Hacioglu M; Gokyer A; Kucukarda A; Ozcan E; Gokmen I; Uzunoglu S; Cicin I
    J BUON; 2021; 26(5):2196-2201. PubMed ID: 34761635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.
    Harada Y; Kakimoto S; Shimizu T
    BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32641305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
    Sneed GT; Lee S; Brown JN; Hammond JM
    Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
    Tanaka H; Hiraga H; Takekuma Y; Harabayashi T; Nagamori S; Endo M; Sugawara M
    Biol Pharm Bull; 2020 May; 43(5):762-766. PubMed ID: 32115446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
    Hackshaw MD; Nagar SP; Parks DC; Miller LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
    Turjap M; Pelcová M; Gregorová J; Šmak P; Martin H; Štingl J; Peš O; Juřica J
    Ther Drug Monit; 2024 Jun; 46(3):321-331. PubMed ID: 38723115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare case: Hallucination associated with pazopanib.
    Demirci NS; Erdem GU; Dogan M; Ozdemir NY; Zengin N
    J Cancer Res Ther; 2015; 11(4):961-2. PubMed ID: 26881556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Atrial flutter probably related to pazopanib: A case report].
    Puebla Villaescusa A; Díaz Gómez E; Salcedo Mingoarranz ÁL; Ramírez Cruz S; Hidalgo Correas FJ; García Díaz B
    Farm Hosp; 2018 Jan; 42(1):33-34. PubMed ID: 29306315
    [No Abstract]   [Full Text] [Related]  

  • 18. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
    Matrana MR; Duran C; Shetty A; Xiao L; Atkinson BJ; Corn P; Pagliaro LC; Millikan RE; Charnsangave C; Jonasch E; Tannir NM
    Eur J Cancer; 2013 Oct; 49(15):3169-75. PubMed ID: 23810246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.